Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Smoking Relapse Prevention in Schizophrenia

NCT00320697
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Smokers
Interventions
bupropion + nicotine patch + nicotine gum or lozenges, Placebo pill + placebo patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

NCT04659161
View directory record Official record
Conditions
Schizophrenia, Schizophrenia; Psychosis
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders

NCT02097563
View directory record Official record
Conditions
Mood Disorders, Psychotic Disorders
Interventions
High Intensity Training, Low Intensity Training
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Culver City, California • Granada Hills, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

NCT04820309
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
116
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 3 Interventional

Pharmacy Interventions to Improve Chronic Disease Medication Refill

NCT00469365
View directory record Official record
Conditions
Diabetes, Hypertension, Hyperlipidemia, Heart Diseases, Depression, Psychoses
Interventions
pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
3,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2008 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

NCT00616798
View directory record Official record
Conditions
Schizophrenia
Interventions
RO4917838, Placebo, Standard antipsychotic therapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Granada Hills, California • Los Angeles, California • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

NCT01012167
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Galantamine, Placebo-Oxytocin, Placebo-Galantamine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Luteolin for the Treatment of People With Schizophrenia

NCT05204407
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Luteolin, Placebo
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Staccato Loxapine in Agitation (Proof of Concept)

NCT00369577
View directory record Official record
Conditions
Schizophrenia
Interventions
Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Upland, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

NCT00176436
View directory record Official record
Conditions
Schizophrenia
Interventions
Diet support group, Group counseling and exercise
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 23, 2026, 5:05 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Perceptual Deficits in Schizophrenia

NCT02337439
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sensory Information Processing Training, Active Control Training
Behavioral
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 23, 2026, 5:05 PM EDT
Not yet recruiting Not applicable Interventional

Feasibility Trial of a Parent Peer-Co-Led Caregiver Group for Pediatric Early Onset Schizophrenia Spectrum Disorders

NCT07867964
View directory record Official record
Conditions
Schizophrenia; Psychosis
Interventions
Group Therapy, Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional

Taking Action for College Students

NCT06700902
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder, Schizophrenia
Interventions
Taking Action
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

NCT00088465
View directory record Official record
Conditions
Schizophrenic Disorders, Schizoaffective Disorder
Interventions
Intramuscular olanzapine depot
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 76 Years
Enrollment
931 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
21
States / cities
Orange, California • Pasadena, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Adults With Schizophrenia

NCT01903837
View directory record Official record
Conditions
Schizophrenia
Interventions
Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 23, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

NCT00517075
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 23, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

NCT03351244
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 23, 2026, 5:05 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

NCT07344948
View directory record Official record
Conditions
Healthy Participants, Schizophrenia Diagnosis
Interventions
NTX-253, Placebo
Drug
Lead sponsor
Neurosterix
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 23, 2026, 5:05 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Brain Tissue Collection for Neuropathological Studies

NCT00001260
View directory record Official record
Conditions
Bipolar Disorder, Depression, Anxiety Disorders, Schizophrenia, Tourette's Syndrome, Brain Diseases
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
2,161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1990 – 2017
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

NCT02420015
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Nicotine replacement therapy, Bupropion, cognitive-behavioral smoking cessation counseling, Mobile Contingency Management, Stay Quit Coach, SMS text messaging
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 23, 2026, 5:05 PM EDT
Terminated Phase 4 Interventional

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

NCT00314613
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic/Risperidone Consta
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 23, 2026, 5:05 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

NCT00211562
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Omega 3, Vitamin E+C
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 23, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

NCT02202213
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Lu AF11167
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 23, 2026, 5:05 PM EDT